5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Skeletal O
muscle O
effects O
( O
e.g. O
, O
myopathy O
and O
rhabdomyolysis O
) O
: O
Risks O
increase O
when O
higher O
doses O
are O
used O
concomitantly O
with O
cyclosporine O
and O
strong O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
clarithromycin O
, O
itraconazole O
, O
HIV O
protease O
inhibitors O
) O
. O

Predisposing O
factors O
include O
advanced O
age O
( O
> O
65 O
) O
, O
uncontrolled O
hypothyroidism O
, O
and O
renal O
impairment O
. O

Rare O
cases O
of O
rhabdomyolysis O
with O
acute O
renal O
failure O
secondary O
to O
myoglobinuria O
have O
been O
reported O
. O

Advise O
patients O
to O
promptly O
report O
to O
their O
physician O
unexplained O
and/or O
persistent O
muscle O
pain O
, O
tenderness O
, O
or O
weakness O
. O

LIPITOR O
therapy O
should O
be O
discontinued O
if O
myopathy O
is O
diagnosed O
or O
suspected O
( O
5.1 O
, O
8.5 O
) O
. O

* O
Liver O
enzyme O
abnormalities O
: O
Persistent O
elevations O
in O
hepatic O
transaminases O
can O
occur O
. O

Check O
liver O
enzyme O
tests O
before O
initiating O
therapy O
and O
as O
clinically O
indicated O
thereafter O
( O
5.2 O
) O
. O

* O
A O
higher O
incidence O
of O
hemorrhagic O
stroke O
was O
seen O
in O
patients O
without O
CHD O
but O
with O
stroke O
or O
TIA O
within O
the O
previous O
6 O
months O
in O
the O
LIPITOR O
80 O
mg O
group O
vs O
. O
placebo O
( O
5.5 O
) O
. O

5.1 O
Skeletal O
Muscle O
Rare O
cases O
of O
rhabdomyolysis B-OSE_Labeled_AE
with O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
myoglobinuria B-OSE_Labeled_AE
have O
been O
reported O
with O
LIPITOR O
and O
with O
other O
drugs O
in O
this O
class O
. O

A O
history O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
may O
be O
a O
risk O
factor O
for O
the O
development O
of O
rhabdomyolysis B-NonOSE_AE
. O

Such O
patients O
merit O
closer O
monitoring O
for O
skeletal O
muscle O
effects O
. O

Atorvastatin O
, O
like O
other O
statins O
, O
occasionally O
causes O
myopathy B-OSE_Labeled_AE
, O
defined O
as O
muscle B-NonOSE_AE
aches I-NonOSE_AE
or O
muscle B-NonOSE_AE
weakness I-NonOSE_AE
in O
conjunction O
with O
increases B-NonOSE_AE
in I-NonOSE_AE
creatine I-NonOSE_AE
phosphokinase I-NonOSE_AE
( I-NonOSE_AE
CPK I-NonOSE_AE
) O
values O
> O
10 O
times O
ULN O
. O

The O
concomitant O
use O
of O
higher O
doses O
of O
atorvastatin O
with O
certain O
drugs O
such O
as O
cyclosporine O
and O
strong O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
clarithromycin O
, O
itraconazole O
, O
and O
HIV O
protease O
inhibitors O
) O
increases O
the O
risk O
of O
myopathy B-NonOSE_AE
/ O
rhabdomyolysis B-NonOSE_AE
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
IMNM I-OSE_Labeled_AE
) O
, O
an O
autoimmune B-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
, O
associated O
with O
statin O
use O
. O

IMNM B-NonOSE_AE
is O
characterized O
by O
: O
proximal B-NonOSE_AE
muscle I-NonOSE_AE
weakness I-NonOSE_AE
and O
elevated B-NonOSE_AE
serum I-NonOSE_AE
creatine I-NonOSE_AE
kinase I-NonOSE_AE
, O
which O
persist O
despite O
discontinuation O
of O
statin O
treatment O
; O
muscle O
biopsy O
showing O
necrotizing B-NonOSE_AE
myopathy I-NonOSE_AE
without O
significant O
inflammation B-NonOSE_AE
; O
improvement O
with O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

Myopathy B-NonOSE_AE
should O
be O
considered O
in O
any O
patient O
with O
diffuse O
myalgias B-NonOSE_AE
, O
muscle B-NonOSE_AE
tenderness O
or O
weakness I-NonOSE_AE
, O
and/or O
marked O
elevation B-NonOSE_AE
of I-NonOSE_AE
CPK I-NonOSE_AE
. O

Patients O
should O
be O
advised O
to O
report O
promptly O
unexplained O
muscle B-NonOSE_AE
pain I-NonOSE_AE
, O
tenderness O
, O
or O
weakness O
, O
particularly O
if O
accompanied O
by O
malaise B-NonOSE_AE
or O
fever B-NonOSE_AE
or O
if O
muscle B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
persist O
after O
discontinuing O
LIPITOR O
. O

LIPITOR O
therapy O
should O
be O
discontinued O
if O
markedly O
elevated B-NonOSE_AE
CPK I-NonOSE_AE
levels I-NonOSE_AE
occur O
or O
myopathy B-NonOSE_AE
is O
diagnosed O
or O
suspected O
. O

The O
risk O
of O
myopathy B-NonOSE_AE
during O
treatment O
with O
drugs O
in O
this O
class O
is O
increased O
with O
concurrent O
administration O
of O
cyclosporine O
, O
fibric O
acid O
derivatives O
, O
erythromycin O
, O
clarithromycin O
, O
the O
hepatitis O
C O
protease O
inhibitor O
telaprevir O
, O
combinations O
of O
HIV O
protease O
inhibitors O
, O
including O
saquinavir O
plus O
ritonavir O
, O
lopinavir O
plus O
ritonavir O
, O
tipranavir O
plus O
ritonavir O
, O
darunavir O
plus O
ritonavir O
, O
fosamprenavir O
, O
and O
fosamprenavir O
plus O
ritonavir O
, O
niacin O
, O
or O
azole O
antifungals O
. O

Physicians O
considering O
combined O
therapy O
with O
LIPITOR O
and O
fibric O
acid O
derivatives O
, O
erythromycin O
, O
clarithromycin O
, O
a O
combination O
of O
saquinavir O
plus O
ritonavir O
, O
lopinavir O
plus O
ritonavir O
, O
darunavir O
plus O
ritonavir O
, O
fosamprenavir O
, O
or O
fosamprenavir O
plus O
ritonavir O
, O
azole O
antifungals O
, O
or O
lipid-modifying O
doses O
of O
niacin O
should O
carefully O
weigh O
the O
potential O
benefits O
and O
risks O
and O
should O
carefully O
monitor O
patients O
for O
any O
signs O
or O
symptoms O
of O
muscle B-NonOSE_AE
pain I-NonOSE_AE
, O
tenderness B-NonOSE_AE
, O
or O
weakness B-NonOSE_AE
, O
particularly O
during O
the O
initial O
months O
of O
therapy O
and O
during O
any O
periods O
of O
upward O
dosage O
titration O
of O
either O
drug O
. O

Lower O
starting O
and O
maintenance O
doses O
of O
atorvastatin O
should O
be O
considered O
when O
taken O
concomitantly O
with O
the O
aforementioned O
drugs O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Periodic O
creatine O
phosphokinase O
( O
CPK O
) O
determinations O
may O
be O
considered O
in O
such O
situations O
, O
but O
there O
is O
no O
assurance O
that O
such O
monitoring O
will O
prevent O
the O
occurrence O
of O
severe O
myopathy B-NonOSE_AE
. O

Prescribing O
recommendations O
for O
interacting O
agents O
are O
summarized O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
Drug O
Interactions O
( O
7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Table O
2 O
. O

Drug O
Interactions O
Associated O
with O
Increased O
Risk O
of O
Myopathy/Rhabdomyolysis O
Interacting O
Agents O
Prescribing O
Recommendations O
Cyclosporine O
, O
HIV O
protease O
inhibitors O
( O
tipranavir O
plus O
ritonavir O
) O
, O
hepatitis O
C O
protease O
inhibitor O
( O
telaprevir O
) O
Avoid O
atorvastatin O
HIV O
protease O
inhibitor O
( O
lopinavir O
plus O
ritonavir O
) O
Use O
with O
caution O
and O
lowest O
dose O
necessary O
Clarithromycin O
, O
itraconazole O
, O
HIV O
protease O
inhibitors O
( O
saquinavir O
plus O
ritonavir O
[ O
note O
: O
Use O
with O
caution O
and O
with O
the O
lowest O
dose O
necessary O
( O
12.3 O
) O
] O
, O
darunavir O
plus O
ritonavir O
, O
fosamprenavir O
, O
fosamprenavir O
plus O
ritonavir O
) O
Do O
not O
exceed O
20 O
mg O
atorvastatin O
daily O
HIV O
protease O
inhibitor O
( O
nelfinavir O
) O
Hepatitis O
C O
protease O
inhibitor O
( O
boceprevir O
) O
Do O
not O
exceed O
40 O
mg O
atorvastatin O
daily O
Cases O
of O
myopathy B-NonOSE_AE
, O
including O
rhabdomyolysis B-NonOSE_AE
, O
have O
been O
reported O
with O
atorvastatin O
co-administered O
with O
colchicine O
, O
and O
caution O
should O
be O
exercised O
when O
prescribing O
atorvastatin O
with O
colchicine O
[ O
see O
Drug O
Interactions O
( O
7.11 O
) O
] O
. O

LIPITOR O
therapy O
should O
be O
temporarily O
withheld O
or O
discontinued O
in O
any O
patient O
with O
an O
acute O
, O
serious O
condition O
suggestive O
of O
a O
myopathy B-NonOSE_AE
or O
having O
a O
risk O
factor O
predisposing O
to O
the O
development O
of O
renal B-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
rhabdomyolysis B-NonOSE_AE
( O
e.g. O
, O
severe O
acute B-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
hypotension B-Not_AE_Candidate
, O
major O
surgery O
, O
trauma O
, O
severe O
metabolic B-Not_AE_Candidate
, O
endocrine O
and O
electrolyte O
disorders I-Not_AE_Candidate
, O
and O
uncontrolled B-Not_AE_Candidate
seizures I-Not_AE_Candidate
) O
. O

5.2 O
Liver B-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
Statins O
, O
like O
some O
other O
lipid-lowering O
therapies O
, O
have O
been O
associated O
with O
biochemical O
abnormalities B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
. O

Persistent O
elevations B-OSE_Labeled_AE
( O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
[ O
ULN O
] O
occurr O
in I-OSE_Labeled_AE
g O
on O
2 O
or O
more O
occasions O
) O
in O
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
occurred O
in O
0.7 O
% O
of O
patients O
who O
received O
LIPITOR O
in O
clinical O
trials O
. O

The O
incidence O
of O
these O
abnormalities O
was O
0.2 O
% O
, O
0.2 O
% O
, O
0.6 O
% O
, O
and O
2.3 O
% O
for O
10 O
, O
20 O
, O
40 O
, O
and O
80 O
mg O
, O
respectively O
. O

One O
patient O
in O
clinical O
trials O
developed O
jaundice B-OSE_Labeled_AE
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
LFT O
) O
in O
other O
patients O
were O
not O
associated O
with O
jaundice B-NonOSE_AE
or O
other O
clinical O
signs O
or O
symptoms O
. O

Upon O
dose O
reduction O
, O
drug O
interruption O
, O
or O
discontinuation O
, O
transaminase O
levels O
returned O
to O
or O
near O
pretreatment O
levels O
without O
sequelae O
. O

Eighteen O
of O
30 O
patients O
with O
persistent B-NonOSE_AE
LFT I-NonOSE_AE
elevations I-NonOSE_AE
continued O
treatment O
with O
a O
reduced O
dose O
of O
LIPITOR O
. O

It O
is O
recommended O
that O
liver O
enzyme O
tests O
be O
obtained O
prior O
to O
initiating O
therapy O
with O
LIPITOR O
and O
repeated O
as O
clinically O
indicated O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
taking O
statins O
, O
including O
atorvastatin O
. O

If O
serious O
liver B-NonOSE_AE
injury I-NonOSE_AE
with O
clinical O
symptoms O
and/or O
hyperbilirubinemia B-NonOSE_AE
or O
jaundice B-NonOSE_AE
occurs O
during O
treatment O
with O
LIPITOR O
, O
promptly O
interrupt O
therapy O
. O

If O
an O
alternate O
etiology O
is O
not O
found O
, O
do O
not O
restart O
LIPITOR O
. O

LIPITOR O
should O
be O
used O
with O
caution O
in O
patients O
who O
consume O
substantial O
quantities O
of O
alcohol O
and/or O
have O
a O
history O
of O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Active B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
unexplained B-Not_AE_Candidate
persistent I-Not_AE_Candidate
transaminase I-Not_AE_Candidate
elevations I-Not_AE_Candidate
are O
contraindications O
to O
the O
use O
of O
LIPITOR O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.3 O
Endocrine O
Function O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
and O
fasting O
serum O
glucose O
levels O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIPITOR O
. O

Statins O
interfere O
with O
cholesterol O
synthesis O
and O
theoretically O
might O
blunt O
adrenal O
and/or O
gonadal O
steroid O
production O
. O

Clinical O
studies O
have O
shown O
that O
LIPITOR O
does O
not O
reduce B-NonOSE_AE
basal I-NonOSE_AE
plasma I-NonOSE_AE
cortisol I-NonOSE_AE
concentration I-NonOSE_AE
or O
impair B-NonOSE_AE
adrenal I-NonOSE_AE
reserve I-NonOSE_AE
. O

The O
effects O
of O
statins O
on O
male O
fertility O
have O
not O
been O
studied O
in O
adequate O
numbers O
of O
patients O
. O

The O
effects O
, O
if O
any O
, O
on O
the O
pituitary-gonadal O
axis O
in O
premenopausal O
women O
are O
unknown O
. O

Caution O
should O
be O
exercised O
if O
a O
statin O
is O
administered O
concomitantly O
with O
drugs O
that O
may O
decrease B-NonOSE_AE
the I-NonOSE_AE
levels I-NonOSE_AE
or I-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
endogenous I-NonOSE_AE
steroid I-NonOSE_AE
hormones I-NonOSE_AE
, O
such O
as O
ketoconazole O
, O
spironolactone O
, O
and O
cimetidine O
. O

5.4 O
CNS O
Toxicity O
Brain B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
seen O
in O
a O
female O
dog O
treated O
for O
3 O
months O
at O
120 O
mg/kg/day O
. O

Brain B-NonOSE_AE
hemorrhage I-NonOSE_AE
and O
optic B-NonOSE_AE
nerve I-NonOSE_AE
vacuolation I-NonOSE_AE
were O
seen O
in O
another O
female O
dog O
that O
was O
sacrificed O
in O
moribund O
condition O
after O
11 O
weeks O
of O
escalating O
doses O
up O
to O
280 O
mg/kg/day O
. O

The O
120 O
mg/kg O
dose O
resulted O
in O
a O
systemic O
exposure O
approximately O
16 O
times O
the O
human O
plasma O
area-under-the-curve O
( O
AUC O
, O
0-24 O
hours O
) O
based O
on O
the O
maximum O
human O
dose O
of O
80 O
mg/day O
. O

A O
single O
tonic B-NonOSE_AE
convulsion I-NonOSE_AE
was O
seen O
in O
each O
of O
2 O
male O
dogs O
( O
one O
treated O
at O
10 O
mg/kg/day O
and O
one O
at O
120 O
mg/kg/day O
) O
in O
a O
2-year O
study O
. O

No O
CNS B-NonOSE_AE
lesions I-NonOSE_AE
have O
been O
observed O
in O
mice O
after O
chronic O
treatment O
for O
up O
to O
2 O
years O
at O
doses O
up O
to O
400 O
mg/kg/day O
or O
in O
rats O
at O
doses O
up O
to O
100 O
mg/kg/day O
. O

These O
doses O
were O
6 O
to O
11 O
times O
( O
mouse O
) O
and O
8 O
to O
16 O
times O
( O
rat O
) O
the O
human O
AUC O
( O
0-24 O
) O
based O
on O
the O
maximum O
recommended O
human O
dose O
of O
80 O
mg/day O
. O

CNS B-NonOSE_AE
vascular I-NonOSE_AE
lesions I-NonOSE_AE
, O
characterized O
by O
perivascular B-NonOSE_AE
hemorrhages I-NonOSE_AE
, O
edema B-NonOSE_AE
, O
and O
mononuclear B-NonOSE_AE
cell I-NonOSE_AE
infiltration I-NonOSE_AE
of I-NonOSE_AE
perivascular I-NonOSE_AE
spaces I-NonOSE_AE
, O
have O
been O
observed O
in O
dogs O
treated O
with O
other O
members O
of O
this O
class O
. O

A O
chemically O
similar O
drug O
in O
this O
class O
produced O
optic B-NonOSE_AE
nerve I-NonOSE_AE
degeneration I-NonOSE_AE
( O
Wallerian B-NonOSE_AE
degeneration I-NonOSE_AE
of I-NonOSE_AE
retinogeniculate I-NonOSE_AE
fibers I-NonOSE_AE
) O
in O
clinically O
normal O
dogs O
in O
a O
dose-dependent O
fashion O
at O
a O
dose O
that O
produced O
plasma O
drug O
levels O
about O
30 O
times O
higher O
than O
the O
mean O
drug O
level O
in O
humans O
taking O
the O
highest O
recommended O
dose O
. O

5.5 O
Use O
in O
Patients O
with O
Recent O
Stroke O
or O
TIA O
In O
a O
post-hoc O
analysis O
of O
the O
Stroke B-NonOSE_AE
Prevention O
by O
Aggressive O
Reduction O
in O
Cholesterol O
Levels O
( O
SPARCL O
) O
study O
where O
LIPITOR O
80 O
mg O
vs O
. O
placebo O
was O
administered O
in O
4,731 O
subjects O
without O
CHD B-NonOSE_AE
who O
had O
a O
stroke B-Not_AE_Candidate
or O
TIA B-Not_AE_Candidate
within O
the O
preceding O
6 O
months O
, O
a O
higher O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
was O
seen O
in O
the O
LIPITOR O
80 O
mg O
group O
compared O
to O
placebo O
( O
55 O
, O
2.3 O
% O
atorvastatin O
vs O
. O
33 O
, O
1.4 O
% O
placebo O
; O
HR O
: O
1.68 O
, O
95 O
% O
CI O
: O
1.09 O
, O
2.59 O
; O
p=0.0168 O
) O
. O

The O
incidence O
of O
fatal B-NonOSE_AE
hemorrhagic B-NonOSE_AE
stroke I-NonOSE_AE
was O
similar O
across O
treatment O
groups O
( O
17 O
vs O
. O
18 O
for O
the O
atorvastatin O
and O
placebo O
groups O
, O
respectively O
) O
. O

The O
incidence O
of O
nonfatal O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
was O
significantly O
higher O
in O
the O
atorvastatin O
group O
( O
38 O
, O
1.6 O
% O
) O
as O
compared O
to O
the O
placebo O
group O
( O
16 O
, O
0.7 O
% O
) O
. O

Some O
baseline O
characteristics O
, O
including O
hemorrhagic B-Not_AE_Candidate
and O
lacunar O
stroke I-Not_AE_Candidate
on O
study O
entry O
, O
were O
associated O
with O
a O
higher O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
in O
the O
atorvastatin O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

